Viewing Study NCT04744584



Ignite Creation Date: 2024-05-06 @ 3:45 PM
Last Modification Date: 2024-10-26 @ 1:56 PM
Study NCT ID: NCT04744584
Status: COMPLETED
Last Update Posted: 2023-12-13
First Post: 2021-01-15

Brief Title: Medication Reconciliation in Pulmonary Hypertension
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization: Assistance Publique - Hôpitaux de Paris

Study Overview

Official Title: Optimizing Drug Management of Patients Suffering From Rare Disease Through Medication Reconciliation Proof of Concept in Pulmonary Hypertension
Status: COMPLETED
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: OPTICARE-HTP
Brief Summary: Pulmonary hypertension PH is a life threatening condition In PH pulmonary arterial hypertension PAH and chronic thrombo-embolic chronic pulmonary hypertension CTEPH are two rare diseases requiring specific and complex drug management In France a part of these treatments only available in hospital pharmacies are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects Anticipating medication errors at the begging of the disease is therefore important and could be done through medication reconciliation
Detailed Description: Medication reconciliation MR will be done for patients hospitalized in the French referral center for PH for PAH or CTEPH Detected medication errors will be tracked and fixed by the physician before the end of hospitalization A synthesis of newstopped and modified treatments will be given to the patient as well as his related healthcare professionals community pharmacist and general practioner to ensure the maintaining of the new therapeutic management and the understanding of drugs modification To compare the potential decrease of medication errors promoted by MR a retrospective MR will be also done for patients without MR at 1st hospitalization but at the next one 3 to 12 months after

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2020-A02455-34 OTHER IDRCB None